Karyopharm Therapeutics Inc - KPTI STOCK NEWS

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Kristin Abate as Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Abate, who has been serving as interim principal financial officer and interim principal accounting officer since November 6, 2024, will continue as interim principal financial officer. With over 15 years of finance experience, she joined Karyopharm in July 2019 and previously worked at PricewaterhouseCoopers LLP from 2007 to 2019. She holds a B.S. in Business Administration from Bryant University and a Masters of Science in Accountancy from Boston College.

Karyopharm Therapeutics (Nasdaq: KPTI) announced its upcoming presentations at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentations will showcase data on selinexor across multiple studies.

The presentations include two posters: one examining the efficacy and safety of selinexor, pomalidomide, and dexamethasone (SPd) for relapsed/refractory multiple myeloma, and another studying selinexor's effect on ruxolitinib refractory myelofibrosis. Additionally, their partner Antengene will present data comparing weekly selinexor, bortezomib, and dexamethasone versus twice-weekly bortezomib and dexamethasone in Chinese patients with relapsed/refractory multiple myeloma.

Karyopharm Therapeutics reported Q3 2024 financial results with total revenue of $38.8 million, including U.S. XPOVIO net product revenue of $29.5 million. The company narrowed its full-year 2024 guidance, projecting total revenue of $145.0-155.0 million and U.S. XPOVIO net product revenue of $110.0-115.0 million. Following FDA alignment, the Phase 3 SENTRY trial in myelofibrosis will use Absolute Change in Total Symptom Score as a co-primary endpoint, with top-line data expected in 2H 2025. The company reported a net loss of $32.1 million for Q3 2024 and had cash reserves of $133.9 million as of September 30, 2024.

Karyopharm Therapeutics (Nasdaq: KPTI) has granted 10,500 restricted stock units (RSUs) to three newly-hired employees as of October 31, 2024. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and will vest over three years, with 33 1/3% vesting annually. The grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of employment termination following a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024. The management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day. The presentation will include financial results and company updates, with dial-in numbers provided for both local and international participants. A live webcast with slides will be available on the company's investor website, with an archived version accessible approximately two hours after the event.

Karyopharm Therapeutics (Nasdaq: KPTI) announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.

Phase 1 trial data showed promising results with 79% of patients achieving SVR35 and an average Abs-TSS improvement of 18.5 points at week 24 when combining selinexor with ruxolitinib, compared to historical data showing less than 50% SVR35 achievement with JAK inhibitor monotherapy.

Karyopharm Therapeutics (Nasdaq: KPTI) has announced a conference call and webcast scheduled for October 31, 2024, at 8:00 a.m. ET. The event will feature leading myelofibrosis experts Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai. They will provide a favorable study design update on the company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis.

The conference call will be accessible via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with slides will be available on the company's investor website, with an archived version available approximately two hours after the event.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted on September 30, 2024, under the company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSU awards will vest over a three-year period, with 33 1/3% of the shares vesting on each anniversary of the Grant Date, subject to continued employment. In the event of a "change in control event" followed by termination for "good reason" or without "cause" within one year, the RSUs will become immediately exercisable in full.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 22,050 restricted stock units (RSUs) to five newly-hired employees. These RSU awards, granted on August 31, 2024, are part of the company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In case of a 'change in control event' followed by termination under specific conditions within a year, the RSUs will become fully exercisable.